# Why Kina | BYOM

URL: https://byom.co/why  
Markdown: https://byom.co/why.md  
Last updated: 2026-10-04

> Kina is named after kinase, the working part of the CDKL5 protein. BYOM is built by a founder whose daughter lives with CDKL5 deficiency disorder, and part of the profit BYOM makes goes to research.

## The name

Kina is the AI operator in BYOM.

Kina is named after kinase. CDKL5 is a kinase: a protein that passes signals on by switching other proteins on and off. Kina passes work on the way a kinase passes a signal: it drafts the change, and a person on your team approves it before anything happens.

Maggie, the daughter of BYOM's founder, lives with CDKL5 deficiency disorder. BYOM is built alongside that.

The CDKL5 protein, drawn from the structure AlphaFold predicts for it (AF-O76039-F1), turns on the Kina home screen and on the BYOM login page.

Research is moving: the first medicine approved for seizures in CDKL5 deficiency disorder arrived in 2022, and gene therapy research is under way.

A share of the profit BYOM makes goes to research into treatments and cures for CDKL5 deficiency disorder, and BYOM helps research institutions worldwide use AI on the tools and data they already have.

## Questions

- Why is Kina called Kina? Kina is named after kinase, the working part of the CDKL5 protein: it passes signals on, switching other proteins on and off so the brain can develop.
- What is Kina? Kina is the AI operator in BYOM. It does the routine work in your store, and every change needs a person on your team to approve it.
- Why was BYOM built this way? Our founder has a daughter, Maggie, who lives with CDKL5 deficiency disorder. BYOM is built alongside that, every day. It is why every change needs a person to approve it, and why part of what BYOM earns goes back into the science.
- Does BYOM give profit to CDKL5 research? A share of the profit BYOM makes goes to research into treatments and cures for CDKL5 deficiency disorder.
- How does BYOM help research institutions? We help research institutions around the world use AI on the tools and data they already have.
- What progress has CDKL5 research made? The first medicine approved for seizures in CDKL5 deficiency disorder arrived in 2022, and more treatments are being studied. Gene therapy research for CDKL5 is moving forward.
- Where does the protein on this page come from? It is the CDKL5 protein, drawn from the structure AlphaFold predicts for it (AF-O76039-F1).